Peri-Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor-Informed Assay in Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma.
A personalized blood test can track treatment response and spot early cancer return in head-and-neck cancer patients at highest risk.
This prospective study validated a customized, tumor-informed NGS-based ctDNA assay for peri-operative monitoring in HPV-negative locally advanced HNSCC, a high-risk group with limited liquid biopsy data. The approach could improve treatment monitoring and early recurrence detection in this poor-prognosis subgroup.
What the study was
- Study design
- Prospective cohort study
- Population
- HPV-negative locally advanced head and neck squamous cell carcinoma (HNSCC) patients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- International Journal of Cancer
Why it surfaced
Tumor-informed ctDNA assay in underrepresented HNSCC subtype; incremental value for liquid biopsy surveillance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.